ARIAD Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals

ARIA 23.99

0.0%

Feb 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: jaybe	7/2/2016 9:41:20 PM
	of 4474

More details about valuation of Ariad Europe can be found in Incyte's 8-K/A... From Exhibit 99.3 Preliminary Estimate of Purchase Price Consideration The following table represents the preliminary estimate of total purchase price transferred to effect the Acquisition (in thousands): PURCHASE CONSIDERATION Upfront payments $ 140,000 Contingent consideration 293,000 Total purchase consideration $ 433,000 ARIAD will be eligible to receive from Incyte Europe tiered royalties of between 32% and 50% on net sales of Iclusig in the Territory and up to $135.0 million in potential future oncology development and regulatory approval milestone payments. The Company determined acquisition date fair value of contingent consideration to be $293.0 million, inclusive of the aforementioned royalties on future net sales." incyte.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next